Toca­gen stream­lines piv­otal plans; Wave Life Sci­ences cuts rib­bon on new man­u­fac­tur­ing plant

→ San Diego-based Toca­gen $TO­CA has stream­lined its Phase III plans for To­ca 511 & To­ca FC as a new ther­a­py for brain can­cer. The biotech is do­ing away with the orig­i­nal Phase II/III ap­proach and go­ing straight in­to a piv­otal study.

→ Cam­bridge, MA-based Wave Life Sci­ences has opened a new 90,000-square-foot man­u­fac­tur­ing fa­cil­i­ty in Lex­ing­ton. Over the longterm the com­pa­ny says the fa­cil­i­ty has room for up to 200 staffers. “The ex­pan­sion of our man­u­fac­tur­ing ca­pa­bil­i­ties is a crit­i­cal mile­stone in our evo­lu­tion as a clin­i­cal-stage com­pa­ny and a fur­ther com­mit­ment to our pledge of pro­vid­ing much need­ed ther­a­pies to pa­tients liv­ing with se­ri­ous, ge­net­i­cal­ly-de­fined dis­eases,” said CEO Paul Bol­no.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER